One example is the LuTectomy (41) trial which aims to explore the dosimetry, efficacy, and toxicity of the lutetium-PSMA treatment early on in men with high-risk localized/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection. The gene discussed is FOLH1; the disease is prostate cancer.